Pfizer Restructuring Charges decreased by 92.8% to $10.00M in Q1 2024 compared to the prior quarter. Year-over-year, this metric grew by 122.7%, from -$44.00M to $10.00M. This increase may warrant attention — for this metric, lower values are generally preferred.
Frequent or large charges may indicate operational instability or a need for significant strategic pivots, while occasional charges are standard in large-scale transformations.
Restructuring charges are one-time costs associated with reorganizing a company's operations, such as severance pay, fac...
Used by analysts to identify non-recurring items that distort year-over-year operating comparisons.
is_restructuring_charges| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q1 '24 | |
|---|---|---|---|---|---|---|---|---|
| Value | -$5.00M | $643.00M | $43.00M | $147.00M | $177.00M | -$44.00M | $138.00M | $10.00M |
| QoQ Change | — | >999% | -93.3% | +241.9% | +20.4% | -124.9% | +413.6% | -92.8% |
| YoY Change | — | — | — | >999% | -72.5% | -202.3% | -6.1% | +122.7% |
| Segment | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Biopharma | $50.00M | $62.00M | $246.00M | -$28.00M | $4.00M | $1.00M | $617.00M | $47.00M |
| Total | $147.00M | $177.00M | — | -$44.00M | $138.00M | — | — | — |